- Home
- AIM vs AMST Comparison
AIM vs AMST Comparison
Compare AIM & AMST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- AMST
- Stock Information
- Founded
- AIM 1966
- AMST 2017
- Country
- AIM United States
- AMST United States
- Employees
- AIM N/A
- AMST N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- AMST Computer Software: Prepackaged Software
- Sector
- AIM Health Care
- AMST Technology
- Exchange
- AIM Nasdaq
- AMST Nasdaq
- Market Cap
- AIM 8.8M
- AMST 7.4M
- IPO Year
- AIM N/A
- AMST 2020
- Fundamental
- Price
- AIM $0.12
- AMST $2.44
- Analyst Decision
- AIM Strong Buy
- AMST
- Analyst Count
- AIM 2
- AMST 0
- Target Price
- AIM $2.75
- AMST N/A
- AVG Volume (30 Days)
- AIM 476.8K
- AMST 46.7K
- Earning Date
- AIM 03-27-2025
- AMST 05-09-2025
- Dividend Yield
- AIM N/A
- AMST N/A
- EPS Growth
- AIM N/A
- AMST N/A
- EPS
- AIM N/A
- AMST N/A
- Revenue
- AIM $170,000.00
- AMST $86,115.00
- Revenue This Year
- AIM N/A
- AMST N/A
- Revenue Next Year
- AIM $1,693.10
- AMST N/A
- P/E Ratio
- AIM N/A
- AMST N/A
- Revenue Growth
- AIM N/A
- AMST N/A
- 52 Week Low
- AIM $0.11
- AMST $1.85
- 52 Week High
- AIM $0.62
- AMST $6.27
- Technical
- Relative Strength Index (RSI)
- AIM 42.13
- AMST 45.55
- Support Level
- AIM $0.11
- AMST $2.34
- Resistance Level
- AIM $0.16
- AMST $2.67
- Average True Range (ATR)
- AIM 0.01
- AMST 0.19
- MACD
- AIM 0.00
- AMST 0.03
- Stochastic Oscillator
- AIM 5.00
- AMST 35.14
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.